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Sllmmary 
Monoclonal antibodies (mAb) have been raised against Plasmodium fakiparum  gametocyte stage 
protein extracts,  in an effort to identify novel parasite  antigens that might mediate malaria 
transmission-blocking immunity, mAb 1A1 identified Pfs2400,  a sexual stage-specific antigen 
of greater than 2 megadaltons, that is associated with the outer leaflet of the parasitophorous 
vacuole membrane in mature circulating gametocyte-infected red blood cells. Upon induction 
of gametogenesis, Pfs2400 partitions between the gamete plasmalemma and the degenerating 
erythrocyte membrane. The antigen is no longer detectable in the fully emerged gamete, mAb 
1A1 dramatically reduces the number of oocysts formed in P.falci~rum gametocyte-fed mosquitoes. 
The cognate antigen is probably the product of the Pfll.1 gene (Scheff et al. 1988. EMBO [Eur. 
Mol. Biol. Organ.]J. 7:1129) on the basis that a peptide composed of two copies of the degenerate 
nine amino acid repeat sequence in the Pill.1 protein, can inhibit binding of mAblA1 to the 
native antigen. The mechanism of transmission inhibition mediated by the Pfs2400 is discussed. 
M 
alaria transmission-blocking immunity is the concept 
that immunity can be induced in humans against the 
parasite stages that develop in the mosquito. The human im- 
mune factors could then function after a blood meal, against 
vulnerable gametes or later sporogonic stages, to inhibit de- 
velopment of the parasite in the mosquito (1). Several labora- 
tories are presently trying to develop a transmission-blocking 
vaccine for the human malaria parasite, Plasmodiumfakiparum 
(2-6). A successful transmission-blocking component for a 
multisubunit vaccine, that would also target the malaria life 
cycle stages that develop in humans, is predicted to reduce 
the transmission of antigenic variants that arise naturally or 
as a result of drug or immune pressure (2, 7). Reducing the 
geographic spread of drug or asexual vaccine-resistant  vari- 
ants in human populations would be a major contribution 
to malaria control. Although sterile immunity is unlikely, 
especially in areas of high transmission, a transmission-blocking 
vaccine would probably have a significant effect on the number 
of malaria  infections in areas of low transmission, such as 
Sri Lanka (8). 
Within RBC, the malaria parasite multiplies asexually or 
differentiates  sexually  into  male and  female  gametocytes. 
Gametocytes can continue developing only in a mosquito, 
where they emerge from the RBC and develop into extracel- 
lular gametes. Fertilization gives rise to zygotes which trans- 
form into motile ookinetes. These cross the gut wall and trans- 
form into oocysts. Sporozoites multiply  within these structures, 
and after their release from mature, ruptured oocysts, can be 
inoculated into another individual to initiate a new infection. 
Any of these steps in sexual development represent potential 
targets for transmission intervention. 
It has been shown for several species of Plasmodia, that an- 
tibodies induced by immunization or natural infection which 
are directed against gamete or zygote surface antigens, can 
indeed inhibit development of the malaria parasite when in- 
gested with the blood meal (6, 9-13). These antibodies are 
effective at three distinct points after gametogenesis: (a) fer- 
tilization of the macrogamete by the microgamete (14); (b) 
transformation of the ookinete into an oocyst (14); and (c) 
production of sporozoites within oocysts (15). The P.faki~rum 
gamete surface antigens, Pfs230 and Pfs48/45, function as 
targets  of antigamete antibodies,  but  display  limited im- 
munogenicity in humans (16, 17). The early sexual stage an- 
tigen, Pfg27/25, is recognized by antibodies that can mediate 
transmission inhibition (5). However the antigen is not sur- 
face exposed during sexual development, and the mechanism 
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The most promising target is the zygote surface antigen, Pfs25 
(3, 4). Antibodies against this antigen inhibit both the de- 
velopment of the ookinete to an oocyst in the mosquito gut 
(14) and production of sporozoites (15). The Pfs25 is con- 
served between parasites isolated worldwide (18), and is highly 
immunogenic in experimental animals (3). However, a desir- 
able feature of a third world vaccine is that a single inoculating 
dose should be effective and long-lasting, and the Pfs25 does 
not function as an immunogen in natural infections (19). 
Therefore, reinfection will not provide a natural boost, and 
alternative methods of administration must be devised  to 
generate'long-term protection from limited immunizations 
in the field. 
We sought to identify novel sexual blood stage antigens 
that might render the parasite vulnerable to human antibodies 
and other immune factors in the mosquito blood meal, as 
these antigens might be expected to provide a boost upon 
parasite infection. Our goal was to produce mAbs that would 
recognize linear epitopes of gametocyte stage-specific antigens, 
that might be easily incorporated into a muhisubunit pep- 
tide vaccine.  A  possible  transmission-blocking target was 
selected for functional studies, on the basis of its localization 
within the parasite. 
This paper reports the generation of a mAb that recog- 
nizes a linear sequence of the P. falciparum  11.1 gene product 
(20).  The biochemical and immunological characterization 
of Pf11.1 has been obscured by its extensive cross-reactivity 
with other negatively charged P.fakiparum antigens, including 
Pf155/RESA, the megadalton asexual stage antigen Ag332, 
and a 260-kD asexual stage antigen (21-23).  Although the 
gene has been extensively studied, no specific protein product 
has been demonstrated. We show that the Pf11.1 gene product 
is a sexual blood stage antigen with an apparent monomer 
molecular mass of >2 megadaltons. The antigen, which we 
have named Pfs2400, appears in stage I gametocytes, accumu- 
lates during gametocyte maturation, and persists during emer- 
gence of the gametes, mAblA1 significantly  blocks develop- 
ment  of the  sexual  parasites  into  oocysts in  the  infected 
mosquito, and the localization of this antigen during sexual 
development suggests a site of action for the mAb in blocking 
sexual development. 
Materials and Methods 
Parasites.  The P. falciparum  gametocyte-producing NF54 iso- 
late and its clonal derivative, 3D7 (24), were cultured in human 
RBC and human serum from type A + donors, under conditions 
that promote gametocyte  production (25), and modified  by the ad- 
dition of 10 mM glucose to the culture medium. To obtain pure 
gametocytes,  any surviving  asexual trophozoites and schizonts were 
selectively  killed between days 12 and 14 of culture, by suspension 
in 5% (wt/vol) D-sorbitol  in distilled water for 5 min at room tem- 
perature (26). Gametocytes and asexual rings were put back into 
culture for 2 d, after which, gametocytes  were purified  from asexual 
rings by Percoll gradient centrifugation (27). The final gametocyte 
preparation contained <1%  contamination with asexual blood 
stages. In vitro emergence of gametes was induced by incubation 
of garnetocytes  in heat-inactivated  PCS (14), and macrogametes  were 
harvested by Percoll gradient centrifugation  as described (28). 
Asexual parasites were obtained by maintaining the cultures at low 
parasitemias (<2%). 
Immunizations.  Purified  gametocytes were pelleted at 37~ 
washed once in  gametocyte retarding buffer (GRB; 1 170  mM 
NaC1, 10 mM glucose, 10 mM Tris, pH 7.4), and denatured by 
boiling in 3% SDS and 3 mM B-ME. The extract was diluted 30- 
fold with GtLB,  before intraperitoneal injection into BALB/c  mice. 
Each immunizing dose consisted of ~10  s gametocytes. The pri- 
mary immunization was administered in CFA. Subsequent doses, 
administered at  5-wk intervals, were emulsified in  incomplete 
Freund's adjuvant, except for the final boost, given intravenously, 
which consisted of the denatured parasite extract in PBS alone. 
Hybridoma Screening.  Immunized mouse spleen  cells  were fused 
with P3U1 myeloma  cells (29). Undiluted hybridoma supernatants 
were screened for the presence of antigametocyte Ab by indirect 
immunofluorescence  (IFA), on acetone-fixed  blood smears of3D7 
gametocytes and asexual parasites (30). 
MAbIAI.  Log phase hybridoma  cells, producing mAblA1, were 
injected into pristane-primed BALB/c  mice. MAblA1, isotyped as 
an IgG1, was affinity-purified  from ascites using the Affi-Gel  pro- 
tein A MAPS II kit (Bio-Rad Laboratories, Richmond, CA), ac- 
cording to the manufacturer's specifications. 
Other Reagents.  MAb7H11.E8, an IgG1 mAb against the Plas- 
modium brasilianum circumsporozoite protein was provided by Dr. 
Alan Cochrane (New York University Medical  Center, New York). 
The 2.4/2.8  megadalton protein molecular weight marker, titin 
(31), was a kind gift of Dr. Kuan Wang (The University of Texas, 
Austin, TX). 18 amino acid peptides corresponding to each of the 
three consensus repeat sequences from the published P. fakiparum 
11.1 protein sequence (20) were synthesized. P3 is the three amino 
acid repeat peptide (EKD)6. P6 is the six amino acid repeat pep- 
tide (EEEKI.T)3. P9 is the degenerate nine amino acid repeat pep- 
tide [PEE(L/V)VEEV(I/V)]2. 
Immunolocalization of the Pfi2400 during Sexual Development.  3D7 
parasites were cultured  under  conditions  that promote  sexual 
differentiation  (25). Under these conditions, the asexual  parasitemia 
peaks at about day 5, and stage II gametocytes begin to appear 
in the culture at about day 7. Initial immunolocalization in de- 
veloping sexual parasites, was performed by IFA on acetone-fixed 
blood smears (30) of these cultures and also of induced gametes, 
using mAblA1 at 10/zg/ml. The gametocyte stages were classified 
by visual inspection of phase-contrast images, according to the 
description of Carter and Miller (32). Immunofluorescence  of live 
gametes was performed after induction of gametogenesis, without 
further purification. 
For immunoelectron microscopy,  blood stage parasites and ga- 
metes were fixed and embedded in LR White resin (Polyscience, 
Warrington, PA) (33). Fixed P. fakiparum sporozoites (Gary Long 
strain) were embedded in LR Gold resin (Polyscience),  containing 
0.5% benzoin methyl ether as an initiator. Sections  were incubated 
for 20 min in PBS containing 5% nonfat dry milk and 0.01% Tween 
20. Grids were then incubated with mAblA1 in PBT (PBS con- 
taining 1% BSA and 0.01% Tween 20) for 2 h at room tempera- 
ture. Control sections were incubated with normal mouse serum 
or PBT only. After washing in PBT, the grids were incubated for 
1 h in 15 nm gold-labeled  goat anti-mouse IgG (Janssen Pharmaceu- 
tical, Piscataway,  NJ) diluted 1:20 in PBT, rinsed with PBT, fixed 
for 15 min in 2.5% glutaraldehyde,  and then stained  with 2% uranyl 
1 Abbreviations used in this paper: GRB, gametocyte  retarding  buffer; IFA, 
indirect immunofluorescence;  PBT, PBS containing 1% BSA and 0.01% 
Tween 20. 
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examined under electron microscopes (model 100CX; JOEL Ltd., 
Tokyo,  Japan; and model CEM 902; Zeiss, Oberkochen, Germany). 
Western Blot Analysis.  Gametocytes,  macrogametes, asexually 
infected  or control red blood cells  were washed  once in PBS at 37~ 
and extracted with 1% NP-40, in 150 mM NaC1, 50 mM Tris, 
pH 8.0 for 1-2 h on ice. Protease inhibitors were included in the 
extraction buffer as described (34). NP-40 soluble extracts were 
boiled for 5 min in sample buffer (0.8% SDS, 1 M urea, 10 mM 
Tris, pH 8.0, 100 mM DTT), separated  by SDS-PAGE, on a 3-10% 
polyacrylamide  gradient gel prepared without a stacker, and trans- 
ferred electrophoretically  to nitrocellulose.  Nitrocellulose  strips were 
blocked with 3% BSA, 0.3% Tween 20 in 50 mM Tris, pH 7.4, 
150 mM NaC1 (BSA/Tris-buffered  saline containing 0.3% Tween 
20 [TTBS]) for 1 h at room temperature, and incubated with 25 
#g/ml mAb in BSA/TTBS for 1.5 h. After extensive washing in 
BSA/TTBS, blots were probed with lzSI-rabbit anti-mouse IgG 
(New England Nuclear, Boston, MA) diluted to 0.1 #Ci/ml in 
BSA/TTBS for 30 min, washed, dried, and autoradiographed. 
Irarnunoprecipitation.  NP-40 solubilized antigens were immu- 
noprecipitated with mAblA1, and then adsorbed onto protein G 
agarose (Pierce Chemical Co.,  Rockford,  IL) according to the 
manufacturer's protocol.  The immunoprecipitated product  was 
visualized by Western blot analysis. 
Radioiraraunoassay.  Polyvinylchloride  microtiter plates were in- 
cubated overnight with 25 #g/ml of mAblA1 in PBS. mAblA1- 
coated  plates were washed  with  PBS  and  blocked with  3% 
BSA/PBS. Plates were then incubated with NP-40 solubilized  pro- 
teins at about 25 #g/ml in 0.5% NP-40, BSA/PBS, for 2 h at room 
temperature. Captured  antigen was detected by counting,  after 
binding of 12SI-labeled mAblA1. To assay  for peptide inhibition of 
mAblA1  to the native antigen,  labeled mAblA1  at  about  1.5 
x  10  s cpm/well (1.3  x  107 cpm/#g), was predetermined to pro- 
duce a strong signal but not saturate the antigen binding sites. 
nSI-labeled mAblA1 was preincubated with peptides for 2 h at 
room temperature, before binding to parasite antigen trapped on 
plastic. 
Transmission  Inhibition Assays.  Gametocytes  of the P.  fakiparurn 
strain NF54 were cultured in the Tipper system (35). 14 d after 
initiation of the culture, the parasitized red cell suspension  (1.4 ml 
containing about 0.3 ml packed cells) of one tipper vessel was har- 
vested and washed by centrifugation at 560 g for 2 rain in 3 ml 
KPMI 1640 onto a cushion of 0.5 ml KBC, prewarmed to 37~ 
150 #1 of the parasitized  cell preparation were added to a prewarmed 
cocktail consisting of 70 #1 of heat-inactivated human serum plus 
40 #1 of flesh frozen type A+ human serum as a source of  comple- 
ment, and 10 #1 of mAb in PBS. Mixtures were distributed to 
prewarmed (37~  membrane  feeders.  Anopheles  gambiae mosquitoes 
were allowed to feed for 10 rain, and fully fed mosquitoes were 
maintained at 26~  for 6 d. The midguts of 20 mosquitoes fed 
under each condition were examined for oocysts at this time, and 
the degree of transmission was calculated as the geometric mean 
of the number of oocysts. Transmission  inhibition was assessed as 
the percent reduction in this number compared with the average 
oocyst numbers  in  control  mosquitoes, fed in  the  absence of 
mAblA1. 
Results 
mAlx  Nine independent mAb were sdected from a single 
fusion of mouse spleen cells immunized with denatured and 
reduced gametocyte protein extracts, that by IFA, reacted ex- 
clusively with gametocyte-infected RBC. One mAb (1A1), 
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Figure  1.  Immunolocalization  of P. fakipamm epitope recognized  by 
mAblA1, by indirect immunofluorescence.  The  second reagent was 
ftuorescein-conjugated  goat anti-mouse  IgG. Fluorescence  micrographs 
of (a) acetone-fixed  gametocytes.  Roman numerals refer to the distinct 
morphologic stages I-III of gametocyte  development.  (White arrowhead) 
Fluorescing  stage  I gametocym  (b) Live,  activated  gametocytes.  (G) Gameto- 
cyte. (MG)  Macrogametes.  (Arrowheads)  Fluorescing  activated  gametocytes. 
Phase micrographs of the same fields are shown below. 
also demonstrated a fluorescence  pattern consistent with a 
membrane or cytoskeletal association for the cognate antigen 
on acetone-fixed macrogametes. This antigen was chosen for 
further characterization, on the basis that it might be surface 
exposed and accessible to blocking antibodies in the mosquito 
blood meal. 
Immunolocalization,  IFA was used to establish the expres- 
sion pattern of the epitope recognized by mAblA1, during 
sexual development of  P. fakiparura.  Immunofluorescence  was 
positive for all sexual blood stage parasites (Fig. 1). mAblA1 
did not detect uninfected or asexuaLly infected RBC.  The 
faint fluorescence associated with the small intraerythrocytic 
parasite, that looks like a late ring/early trophozoite by phase- 
constrast (Fig. 1 a), is presumably a stage I gametocyte. The 
fluorescence intensity increased in the later gametocytes, from 
stage II onward, which are dearly distinguishable in the phase- 
contrast images. In these more mature gametocytes, the fluores- 
cence pattern is consistent with an antigen localization sur- 
rounding the intraerythrocytic parasite.  Thus,  the antigen 
recognized by mAblA1 is produced very early after commit- 
ment of the parasites  to sexual development, and accumu- 
lates  during gametocyte maturation. 
The accessibility of the 1A1 epitope on the surface of live 
gametes was determined by IFA, as a preliminary evaluation 
of the possibility that this epitope might render the sexual 
parasite vulnerable to human antibodies in the mosquito blood 
meal. Gametocytes were induced to emerge from the infected 
RBC, and parasites were tested for reactivity with mAblAL 
As shown in Fig.  1 b, fluorescence was observed on the sur- 
face  of some,  but  not  all,  of the  live  macrogametes.  In- 
traerythrocytic  gametocytes, visible in the same field by phase- 
contrast microscopy, were not detected by mAblA1. These 
data indicate that mAblA1 recognizes an epitope that is within 
the gametocyte-infected  RBC, and is surface exposed during 
emergence of macrogametes. Its presence on only a subpopu- Figure  2.  Electron  micrographs of P.fakiparum blood stages 
and sporozoite, incubated with mAblA1, followed by gold- 
labeled goat anti-mouse IgG. (a) Erythrocyte  infected with 
an immature gametocyte. (b) Mature gametocyte. (c) Asexual 
ring form. (d) Asexual schizont.  (e) Sporozoite. (E) erythro- 
cyte;  (G) gametocyte;  and (PVM) parasitophorous  vacuole 
membrane. Gold particles (arrows)  are seen in the erythrocyte 
cytoplasm adjacent to the FVM in the mature gametocyte (b). 
Bars: (a, b inset, d,  and e) 0.5/zm;  (b and c) 1.0/zm. 
lation of macrogametes suggests that the antigen might be 
shed from the parasite  surface, before fertilization. 
Precise subceUular localization was determined by immu- 
noelectron microscopy. As soon as sexual parasites could be 
distinguished morphologically from asexual trophozoites, gold 
label was observed. In immature gametocytes (Fig. 2 a), label 
was observed throughout the erythrocyte cytoplasm. Some 
label was found adjacent to the parasitophorous vacuole mem- 
brane.  A few gold particles  were also found in the parasite 
cytoplasm, apparently associated with cytoplasmic vacuoles. 
Mature gametocytes were ultrastructurally characterized 
by a pellicular complex consisting of three sets of membranes 
(36). Immunoelectron  microscopy showed that mAblA1 binds 
to an abundant antigen in the erythrocyte cytoplasm that is 
associated exclusively  with the outer leaflet of the parasitophor- 
ous vacuole membrane (Fig. 2 b and inset), consistent with 
the bright surface-like pattern observed by IFA. A few gold 
particles  were seen in the gametocyte cytoplasm. No gold 
label was observed in asexual rings or schizonts (Fig.  2,  c 
and d), and the epitope was also not detected in sporozoites 
(Fig.  2 e). 
The mAblA1 epitope was also localized in sexual parasites 
that had been induced to emerge from the infected erythro- 
cyte. Fig. 3 a shows an activated gametocyte, with the gold 
label partitioning between the gamete plasmalemma and the 
RBC membrane, Some immunolabeling  is scattered through- 
out the lysed erythrocyte cytoplasm, in association with rem- 
nants of erythrocyte cytoplasm and erythrocyte membrane. 
In this micrograph, the erythrocyte membrane has clearly 
lost its integrity, and appears to be pealing away from the 
emerging gamete. In extracellular gametes, the antigen is no 
longer detected (Fig.  3  b). 
Pfs2400.  The molecular weight of the cognate antigen 
was determined by immunoprecipitation and Western blot 
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induction of gametogenesis. (EPM) Erythrocyte plasmalemma; (GPM) gamete plasmalemma. (b) Mature gamete. Bar, 1.76  #m. 
analysis (Fig. 4).  MAblA1 detects a single parasite antigen 
that comigrates with the 2.4 megadahon subunit of the rabbit 
skeletal muscle protein, titin. The antigen is only present in 
protein extracts  from gametocyte-infected RBCs and from 
emerging macrogametes. It can be detected by mAblA1 under 
both reducing (Fig. 4) and nonreducing conditions (data not 
shown), indicating that the functional epitope is not depen- 
dent upon tertiary conformation or the presence of disulfide 
bonds. No reactivity was detected in protein extracted from 
RBCs infected with asexual stages or from uninfected RBCs. 
In keeping with the nomenclature for newly identified P. Jal- 
ciparum sexual stage antigens of unknown function, we refer 
to the antigen as Pfs2400 for sexual stage-specific  antigen 
with an apparent Mr of 2400. 
As many plasmodial antigens contain tandemly repeated 
amino acid sequences, which are frequently immunodominant, 
a RIA was performed to address the nature of the epitope 
recognized by mAblA1 (Fig. 5). mAblA1 was immobilized 
in plastic wells of microtiter plates,  and used to capture na- 
tive Pfs2400 from P. fakiparum gametocyte protein extracts 
or control proteins. Probing with tracer  amounts of 12sI- 
labeled mAblA1 resulted in a strong signal when gameto- 
cyte proteins were the source of antigen, consistent with the 
possibility that the epitope might be present in multiple copies 
on the antigen. No Pfs2400 was detected in asexual stage 
proteins, BSA, or gametocyte culture supernatant. 
To test directly for the release of Pfs2400 from extracel- 
lular gametes, gametocytes were induced to emerge, and both 
the supernatant and the macrogamete protein extract were 
assayed for the presence of the antigen by RIA. As seen in 
Fig. 5, Pfs2400 can be detected in both the supernatant and 
the cell extract, providing biochemical confirmation of our 
structural data that the antigen is shed from the parasite during 
emergence. No  signal was detected in control FCS. 
Pfs2400 Is the Product of the Pfll.1  Gene.  To determine 
the identity of the antigen and the fine specificity of the epi- 
tope recognized by mAblA1, we tested the possibility that 
the Pfs2400 is the product of the P. falciparum 11.1 gene, a 
recently characterized megadahon antigen distributed in small 
clusters surrounding parasitophorous vacuole membrane in 
mature gametocytes (37). mAblA1 binding to native Pfs2400 
was assayed in the presence and absence of synthetic peptides 
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Figure 6.  Competitive  R.IA reveals  the fine  specificity  of mAblA1. In- 
creasing concentrations of synthetic peptide, P9,  inhibit 12SI-labeled 
mAblA1 binding to native pfs2400 in a dose-dependent fashion. Error 
bars represent  the SD from the mean of triplicate  assays. (Inset)  Compares 
the effects  of synthetic  peptides P3, P6, and P9, on mAblA1 binding to 
native antigen. (O) mAblA1 binding to Pfs2400  in the absence  of inhib- 
itor. The sequences  of  the Pfll.1-derived  repeat  peptides  are given  in Materials 
and Methods. 
Figure 4.  Identification  of  Pfs2400. (.4)  Immunoprecipitation  ofgameto- 
cyte  proteins  (G) and asexual  trophozoite  and schizont  proteins  (AS) with 
mAblA1. Precipitated  protein  was visualized  by Western  blot. The 50-kD 
band is a mAblA1 H chain from the immunoprecipitation  reacting with 
the second  reagent, 12si goat anti-mouse  IgG. (B) Western blot analysis 
of  NP-40  protein  extracts  from  uninfected  red blood  cells (RBC), gameto- 
cytes (G), emerging  macrogametes  (MG), and asexually  infected  red blood 
cells (AS). (M) Molecular  weight standards. In control  experiments,  mAb 
7H11.E8, against the circumsporozoite  protein  from  P. brasilianum,  showed 
no reactivity  with any P. fakiFarum or RBC protein. 
corresponding to each of the three blocks of tandem repeat 
sequences encoded by the Pill.1 gene. As shown in Fig. 6, 
P9, consisting of two copies of the Pf11.1 degenerate nine 
amino acid repeat sequence, inhibited mAblA1 binding to 
Pfs2400 in a dose-dependent manner. Complete inhibition 
was achieved at 50 #g/ml. The other two peptides, P3 and 
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Figure 5.  Pfs2400  occurs  in gametocytes  and emerging  macrogametes, 
and soluble Pfs2400 is released from emerging  gametes. Gametocyte  pro- 
teins (G), asexual  stage  proteins  (AS), control  bovine  serum  albumin (BSA), 
gametocyte  supernatant  (GS), RPMI media  including 10% human serum 
(Med), macrogamete  proteins (MG), macrogamete  supernatant (MS), or 
fetal  calf  serum (FCS)  was added  to mAbLAl-coated  plastic. Protein  sources 
containing Pfs2400 were detected by RIA, with nSI-labeled mAblA1. 
Error bars indicate the SD from the mean of triplicate assays. 
quences in the Pill.1 antigen, respectively, had no inhibitory 
effect on mAblA1 binding to Pfs2400 at concentrations as 
high as 200/~g/ml (Fig. 6, inset). Thus, Pfs2400 is most likely 
the product of the Pf11.1 gene. A peptide consisting of two 
linear repeats of the degenerate nine amino acid repeat se- 
quence, PEE(L/V)VEEV(I/V), contains the minimum  se- 
quence necessary to inhibit mAblA1 binding to the Pfs2400. 
~ansmission Inhibition.  As the surface of  live macrogametes 
is accessible to binding by mAblA1,  at least during emer- 
gence from the RBC,  we sought to determine the ability 
of mAblA1  to block sexual development of the parasite in 
P. fakiparum gametocyte-fed  mosquitoes. Table 1 shows that, 
in three separate experiments, this reagent reduced the for- 
mation of oocysts within the mosquito midgut,  compared 
with mosquitoes fed on control human serum.  In two ex- 
periments,  mAblA1  reduced the mean number of oocysts 
formed by 70 and 80% at a final concentration of only 92.6 
pg/ml. At lower concentrations (Expt. 3), mAblA1 still re- 
duced oocyst formation. Even at  1 ~g/ml, oocyst numbers 
were reduced by 41%, compared with human control serum. 
In this experiment, an unrelated mouse mAb bearing the same 
IgG1 isotype as mAblA1, had little effect on sexual develop- 
ment at  74/~g/ml. 
Discussion 
We have identified a linear  epitope on  the Pfll.1  gene 
product, that can mediate a substantial transmission blockade 
in an antibody-dependent fashion. The parasite load in these 
mosquito-feeding experiments is much higher than what is 
generally found in the field, where most mosquitoes are nat- 
urally infected with only one or a few oocysts (38). Mosquito 
feeding in the presence of a reduced number of gametocytes, 
will assess whether a 70-80%  reduction in oocysts might 
represent real protection. MAblA1, generated during this in- 
vestigation, is specific for Pf11.1, a large sexual stage-specific 
antigen, containing at least three blocks of tandemly repeated 
amino acid sequences (20, 37). Using peptides corresponding 
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Final  No. mosquitoes  Mean no. oocysts/  Mean percent 
Sample  concentration  dissected  Percent infected  mosquito  reduction in oocysts 
IgG /zg/ml 










60  95  30.9 
92.6  20  90  9.3  70 
60  98  45.2 
92.6  20  85  9.2  80 
60  100  102.5 
44.4  20  100  42.7  58 
9.3  20  100  44.2  57 
1.0  20  100  60.0  41 
74.1  20  100  96.1  6 
* Normal human serum. 
Unrelated  mAb. 
to  tandem copies of each of the known repeats,  the fine 
specificity of mAblA1 was shown to be directed against the 
nine amino acid repeat block. 
The Pf11.1 locus is subject to DNA breakage and telomere 
healing, with concomitant loss of gene expression in labora- 
tory isolates (37). Although the truncated Pf11.1 gene was 
observed in a laboratory clone that can initiate sexual devel- 
opment and generate gametocytes in culture,  there was no 
evidence  of  the truncated gene in parasite  DNA isolated  directly 
from 15 patients  (37), suggesting that Pf11.1 expression is 
necessary for some later step in sporogonic development, in 
vivo. 
We suggest that mAblA1 probably inhibits the formation 
of extracellular gametes, because the conserved but degenerate 
Pf11.1 nonapeptide repeats are briefly exposed on live sexual 
parasites during emergence of gametes from activated gameto- 
cytes. Perhaps mAblA1 interferes with the complete shed- 
ding of the RBC and parasitophorous  vacuole membranes. 
Low concentrations (ml0/zg/ml) of transmission-blocking 
mAb directed against Plasmodium vivax gamete surface an- 
tigens have been shown to increase the number of oocysts 
generated in mosquitoes fed on mature P. vivax gametocytes, 
perhaps by cross-linking male and female gametes to facili- 
tate fertilization (11, 39). Transmission enhancement has not 
yet been observed in P.. fakiparum,  and indeed, the presence 
of even lower concentrations (I #g/ml) of mAblA1 does not 
increase oocyst numbers in P. fakiparum-infected  mosquito. 
The data presented here indicate that mAblA1 is probably 
functioning before gamete fertilization,  unless the soluble 
Pf11.1 antigen has a role in sexual  development in the mosquito 
midgut. Since low mAblA1 concentrations in the blood meal 
still produce a dramatic reduction in the number of oocysts 
279  Feng et  al. 
that develop in the infected mosquito, we will test the possi- 
bility that the antibody may  be agglutinating activated  gameto- 
cytes, and also assay the contribution of complement to the 
observed protection. 
Western blot analysis of  both reduced and unreduced blood- 
stage parasite extracts, with mAblA1, demonstrated that the 
Pfll.1 gene product is about 2.4 megadaltons in both gameto- 
cytes and emerging gametes. The antigen does not appear 
to be processed while it is still associated with the activated 
sexual parasite, mAblE10, the mAb reported to identify the 
Pf11.1 gene product, also recognizes a linear epitope contained 
within the nine amino acid repeat (37). However, mAblE10 
detects a smear from gametocyte protein extracts,  that ex- 
tends from the top to the 50-kD region of a gradient gel 
(37). It is possible that mAblE10 cross-reacts  with other nega- 
tively charged gametocyte stage antigens. This is supported 
by the finding that the detailed localization of the mAblE10 
epitope is slightly different from the even distribution of  gold 
label around the parasitophorous vacuole membrane observed 
with  mAblA1.  Alternatively,  as  the  authors  proposed, 
degraded antigen is responsible for the dramatic smear on 
Western blot analysis with mAblE10 (37). 
The Pf11.1 antigen has several features that make it an at- 
tractive candidate for a malaria transmission-blocking  vac- 
cine. The genomic sequence encoding the nine amino acid 
repeats is degenerate, but present in at least 20 isolates from 
eight geographically distinct locations (40, 20), and the en- 
coded repeats can act as a target for mAblAl-mediated inhi- 
bition of sporogonic  development.  In addition,  antibodies 
against the nine amino acid repeats have been reported to 
be present in human immune sera (41, 42), indicating that 
Pf11.1 or one of the glutamate-rich, cross-reacting  P.falcilmrum antigens is immunogenic in a human infection. This sug- 
gests that it should be possible to identify a peptide containing 
a minimum epitope based on this sequence, which is immuno- 
genic in humans. Further, since the antigen is expressed  in 
blood stage parasites  very early after sexual differentiation, 
reinfection might be expected to boost the antibody titers 
to transmission-blocking levels during the 12-14 d gameto- 
cyte maturation time, after a primary immunization with 
Pfll.1-derived epitopes.  Whereas the Pf11.1 six amino acid 
repeat block is absent in some P.fakiparum isolates, the three 
amino acid repeats are also conserved (20), and therefore rep- 
resent a second potential transmission-blocking target. Ex- 
periments are in progress to test the capacity of peptides cor- 
responding to these repeats to elicit polyclonal antibodies that, 
alone or in combination, can mediate a complete transmis- 
sion blockade. 
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